Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H27NO3S2.ClH.H2O |
| Molecular Weight | 460.05 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.CN1C2CCC(C)(C)C1CC(C2)OC(=O)C(O)(C3=CC=CS3)C4=CC=CS4
InChI
InChIKey=ISDSJXYEVLNWPV-UHFFFAOYSA-N
InChI=1S/C21H27NO3S2.ClH.H2O/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18;;/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3;1H;1H2
CNS Activity
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
8 mg single, oral Studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: uditory hallucination, Delirium... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Delirium | 8 mg single, oral Studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
| uditory hallucination | 83.3% | 8 mg single, oral Studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. | 2002 |
|
| Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain. | 1990-09 |
|
| Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients. | 1982 |
|
| Metabolic fate of 6,6,9-trimethyl-9-azabicyclo(3,3,1)non-3 -yl , -di(2-thienyl)glycolate hydrochloride monohydrate (PG-501). | 1972-08 |
|
| [Absorption, distribution and excretion of 14 C-labelled 6,6,9-trimethyl-9-azabicyclo(3,3,1)non-3 -yl a,a-di(2-thienyl)glycolate hydrochloride monohydrate (PG-501)]. | 1972-08 |
|
| [Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent]. | 1971-07 |
|
| Pharmacology of a new anti-parkinsonian drug: KAO-264. | 1971-04 |
Sample Use Guides
1 tablet (4 mg) is administered orally three times a day. In case of taking Pentona 1%, 0.4 g should be administered the same way.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11954326
Created by
admin on Mon Mar 31 21:24:22 GMT 2025 , Edited by admin on Mon Mar 31 21:24:22 GMT 2025
|
PRIMARY | |||
|
65104-02-1
Created by
admin on Mon Mar 31 21:24:22 GMT 2025 , Edited by admin on Mon Mar 31 21:24:22 GMT 2025
|
PRIMARY | |||
|
T64234598Y
Created by
admin on Mon Mar 31 21:24:22 GMT 2025 , Edited by admin on Mon Mar 31 21:24:22 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
